[{"id":"451a8a7f-851d-493a-9270-889080e917a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05086497","created_at":"2021-10-21T13:53:08.372Z","updated_at":"2025-02-25T15:19:19.323Z","phase":"","brief_title":"WBSI Guided Personalized Delivery of TTFields","source_id_and_acronym":"NCT05086497","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation • IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation • IDH wild-type"],"overall_status":"Recruiting","enrollment":" Enrollment 155","initiation":"Initiation: 01/15/2023","start_date":" 01/15/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-11"},{"id":"b172bb8d-07dd-4d40-b459-cb7946457b73","acronym":"NRG-BN007","url":"https://clinicaltrials.gov/study/NCT04396860","created_at":"2021-01-18T21:13:04.295Z","updated_at":"2025-02-25T15:34:40.901Z","phase":"Phase 2/3","brief_title":"Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma","source_id_and_acronym":"NCT04396860 - NRG-BN007","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • TMB • IDH1 • MGMT","pipe":" | ","alterations":" PD-L1 expression • MGMT promoter methylation • IDH1 R132","tags":["PD-L1 • TMB • IDH1 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MGMT promoter methylation • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • temozolomide • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 159","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 04/13/2023","primary_completion_date":" 04/13/2023","study_txt":" Completion: 03/11/2025","study_completion_date":" 03/11/2025","last_update_posted":"2025-02-10"},{"id":"b0a219e9-f08b-4dc8-9baf-aea7746f89fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02287428","created_at":"2021-01-18T10:46:55.814Z","updated_at":"2025-02-25T16:14:11.420Z","phase":"Phase 1","brief_title":"Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM","source_id_and_acronym":"NCT02287428","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • temozolomide • Hiltonol (poly-ICLC) • Neo Vax (NEO-PV-01)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 11/01/2014","start_date":" 11/01/2014","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-12-05"},{"id":"caca578c-aaca-49e5-a97d-ca67554ac90d","acronym":"CLINGLIO","url":"https://clinicaltrials.gov/study/NCT04250922","created_at":"2021-01-18T20:39:26.321Z","updated_at":"2024-07-02T16:34:59.713Z","phase":"Phase 2/3","brief_title":"LAM561 With RT and TMZ for Adults With Glioblastoma","source_id_and_acronym":"NCT04250922 - CLINGLIO","lead_sponsor":"Laminar Pharmaceuticals","biomarkers":" IDH1 • MGMT","pipe":" | ","alterations":" MGMT promoter methylation • IDH wild-type","tags":["IDH1 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Minerval (idroxioleic acid)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 12/01/2019","start_date":" 12/01/2019","primary_txt":" Primary completion: 10/15/2024","primary_completion_date":" 10/15/2024","study_txt":" Completion: 05/30/2025","study_completion_date":" 05/30/2025","last_update_posted":"2024-05-31"},{"id":"b56f4287-89ee-4b31-a0fe-61bc9ba09fe4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05986851","created_at":"2023-08-14T15:10:00.555Z","updated_at":"2024-07-02T16:35:00.485Z","phase":"Phase 2","brief_title":"Azeliragon in MGMT Unmethylated Glioblastoma","source_id_and_acronym":"NCT05986851","lead_sponsor":"Cantex Pharmaceuticals","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation • IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azeliragon (TTP488)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/12/2023","start_date":" 09/12/2023","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-29"},{"id":"3b885732-0c6b-4c16-beb1-fbc5553cef67","acronym":"GlioVax","url":"https://clinicaltrials.gov/study/NCT03395587","created_at":"2021-01-18T16:45:21.670Z","updated_at":"2024-07-02T16:35:04.022Z","phase":"Phase 2","brief_title":"Efficiency of Vaccination With Lysate-loaded Dendritic Cells in Patients With Newly Diagnosed Glioblastoma","source_id_and_acronym":"NCT03395587 - GlioVax","lead_sponsor":"Heinrich-Heine University, Duesseldorf","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation • IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 136","initiation":"Initiation: 03/06/2018","start_date":" 03/06/2018","primary_txt":" Primary completion: 11/06/2026","primary_completion_date":" 11/06/2026","study_txt":" Completion: 03/06/2027","study_completion_date":" 03/06/2027","last_update_posted":"2024-05-14"},{"id":"867a967c-2649-4257-8315-9ba87b5b16ef","acronym":"ENGAGE","url":"https://clinicaltrials.gov/study/NCT03776071","created_at":"2021-01-18T18:40:48.140Z","updated_at":"2024-07-02T16:35:08.333Z","phase":"Phase 3","brief_title":"A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1","source_id_and_acronym":"NCT03776071 - ENGAGE","lead_sponsor":"Denovo Biopharma LLC","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Kinenza (enzastaurin)"],"overall_status":"Completed","enrollment":" Enrollment 260","initiation":"Initiation: 12/16/2020","start_date":" 12/16/2020","primary_txt":" Primary completion: 02/29/2024","primary_completion_date":" 02/29/2024","study_txt":" Completion: 02/29/2024","study_completion_date":" 02/29/2024","last_update_posted":"2024-04-22"},{"id":"50f8b205-06c7-4e3e-b459-1ebbfce2f273","acronym":"","url":"https://clinicaltrials.gov/study/NCT04910022","created_at":"2021-06-02T20:57:18.421Z","updated_at":"2024-07-02T16:35:14.620Z","phase":"Phase 1/2","brief_title":"Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma","source_id_and_acronym":"NCT04910022","lead_sponsor":"Nerviano Medical Sciences","biomarkers":" EGFR • IDH1 • IDH2 • MGMT • TERT","pipe":" | ","alterations":" EGFR mutation • EGFR amplification • MGMT promoter methylation • TERT mutation • IDH wild-type • TERT promoter mutation","tags":["EGFR • IDH1 • IDH2 • MGMT • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR amplification • MGMT promoter methylation • TERT mutation • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • lomustine • itareparib (NMS-293)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-03-15"},{"id":"24b439dc-7d7b-496b-a965-b7e47c369dd2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05743595","created_at":"2023-02-24T16:01:26.750Z","updated_at":"2024-07-02T16:35:16.529Z","phase":"Phase 1","brief_title":"Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma","source_id_and_acronym":"NCT05743595","lead_sponsor":"Washington University School of Medicine","biomarkers":" IDH1 • IDH2 • MGMT","pipe":" | ","alterations":" IDH2 mutation • MGMT promoter methylation • IDH wild-type","tags":["IDH1 • IDH2 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • MGMT promoter methylation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • neoantigen DNA vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/27/2023","start_date":" 10/27/2023","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2024-03-04"},{"id":"2c904db6-1fff-4952-9c6f-25b317ec9aec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04765514","created_at":"2021-02-21T12:52:29.009Z","updated_at":"2024-07-02T16:35:21.679Z","phase":"Phase 2","brief_title":"Chemoradiotherapy Versus Biomarker-Guided Therapy for Elderly and Frail GBM Patients","source_id_and_acronym":"NCT04765514","lead_sponsor":"AHS Cancer Control Alberta","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 121","initiation":"Initiation: 07/27/2022","start_date":" 07/27/2022","primary_txt":" Primary completion: 06/01/2032","primary_completion_date":" 06/01/2032","study_txt":" Completion: 06/01/2032","study_completion_date":" 06/01/2032","last_update_posted":"2024-01-30"},{"id":"bd470247-33b7-45c3-a313-a7729d609e0e","acronym":"NRG-BN011","url":"https://clinicaltrials.gov/study/NCT05095376","created_at":"2021-10-27T15:53:22.431Z","updated_at":"2024-07-02T16:35:23.915Z","phase":"Phase 3","brief_title":"Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma","source_id_and_acronym":"NCT05095376 - NRG-BN011","lead_sponsor":"NRG Oncology","biomarkers":" IDH1 • MGMT","pipe":" | ","alterations":" MGMT promoter methylation • IDH1 R132H • IDH1 R132","tags":["IDH1 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation • IDH1 R132H • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • lomustine"],"overall_status":"Recruiting","enrollment":" Enrollment 306","initiation":"Initiation: 11/29/2021","start_date":" 11/29/2021","primary_txt":" Primary completion: 08/08/2026","primary_completion_date":" 08/08/2026","study_txt":" Completion: 08/08/2031","study_completion_date":" 08/08/2031","last_update_posted":"2024-01-10"},{"id":"43117010-8c09-4b16-8b62-84e304e25621","acronym":"","url":"https://clinicaltrials.gov/study/NCT04893356","created_at":"2021-05-19T11:52:40.134Z","updated_at":"2024-07-02T16:35:31.135Z","phase":"","brief_title":"Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT)","source_id_and_acronym":"NCT04893356","lead_sponsor":"National Cancer Institute, Naples","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation • MGMT expression","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation • MGMT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dacarbazine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 01/20/2021","start_date":" 01/20/2021","primary_txt":" Primary completion: 02/28/2022","primary_completion_date":" 02/28/2022","study_txt":" Completion: 01/20/2025","study_completion_date":" 01/20/2025","last_update_posted":"2023-10-30"},{"id":"cb9542bd-cd4b-4fdd-b230-bd5afa2d9636","acronym":"ARETHUSA","url":"https://clinicaltrials.gov/study/NCT03519412","created_at":"2021-01-18T17:19:32.520Z","updated_at":"2024-07-02T16:35:35.646Z","phase":"Phase 2","brief_title":"Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status","source_id_and_acronym":"NCT03519412 - ARETHUSA","lead_sponsor":"IFOM ETS - The AIRC Institute of Molecular Oncology","biomarkers":" TMB • MGMT","pipe":" | ","alterations":" MSI-H/dMMR • RAS mutation • MGMT promoter methylation • MGMT expression","tags":["TMB • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • RAS mutation • MGMT promoter methylation • MGMT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • temozolomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 01/23/2019","start_date":" 01/23/2019","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-09-27"},{"id":"c5d4896d-d6e6-484b-a31f-c6032c673747","acronym":"","url":"https://clinicaltrials.gov/study/NCT05183204","created_at":"2022-01-10T14:58:24.578Z","updated_at":"2024-07-02T16:35:35.748Z","phase":"Phase 2","brief_title":"Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma","source_id_and_acronym":"NCT05183204","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin • paxalisib (GDC-0084)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 02/14/2022","start_date":" 02/14/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-09-26"},{"id":"e18ab54e-0cbe-4cd0-8f4f-4f35dfe5353c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04868396","created_at":"2021-04-30T11:55:20.150Z","updated_at":"2024-07-02T16:35:39.153Z","phase":"","brief_title":"Patient-derived Glioma Stem Cell Organoids","source_id_and_acronym":"NCT04868396","lead_sponsor":"Maastricht Radiation Oncology","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/10/2021","start_date":" 04/10/2021","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-08-23"},{"id":"d96e48a6-4c6d-486b-94c1-512a7ee12066","acronym":"","url":"https://clinicaltrials.gov/study/NCT00591370","created_at":"2021-01-18T02:11:18.840Z","updated_at":"2025-02-25T15:57:36.572Z","phase":"Phase 2","brief_title":"Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma","source_id_and_acronym":"NCT00591370","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MGMT • IL2","pipe":" | ","alterations":" MGMT promoter methylation","tags":["MGMT • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 01/01/2005","start_date":" 01/01/2005","primary_txt":" Primary completion: 06/01/2008","primary_completion_date":" 06/01/2008","study_txt":" Completion: 06/01/2008","study_completion_date":" 06/01/2008","last_update_posted":"2023-07-25"},{"id":"1e7d842e-e4ca-4d95-b896-1da6f52d2d98","acronym":"","url":"https://clinicaltrials.gov/study/NCT03726515","created_at":"2021-01-18T18:15:36.195Z","updated_at":"2024-07-02T16:35:44.942Z","phase":"Phase 1","brief_title":"CART-EGFRvIII + Pembrolizumab in GBM","source_id_and_acronym":"NCT03726515","lead_sponsor":"University of Pennsylvania","biomarkers":" EGFR • MGMT • TERT","pipe":" | ","alterations":" EGFR amplification • MGMT promoter methylation • TERT mutation • EGFRvIII expression • IDH wild-type • TERT promoter mutation","tags":["EGFR • MGMT • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • MGMT promoter methylation • TERT mutation • EGFRvIII expression • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • LXF821"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 03/11/2019","start_date":" 03/11/2019","primary_txt":" Primary completion: 02/27/2021","primary_completion_date":" 02/27/2021","study_txt":" Completion: 02/27/2021","study_completion_date":" 02/27/2021","last_update_posted":"2023-06-22"},{"id":"2325ad67-a6c7-40b4-b0a4-40263229ded9","acronym":"RIGOLETTO","url":"https://clinicaltrials.gov/study/NCT04933942","created_at":"2021-06-22T15:52:35.716Z","updated_at":"2024-07-02T16:35:47.227Z","phase":"Phase 2","brief_title":"Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma","source_id_and_acronym":"NCT04933942 - RIGOLETTO","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" IDH1 • MGMT","pipe":" | ","alterations":" MGMT promoter methylation • IDH1 R132H • IDH1 R132","tags":["IDH1 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation • IDH1 R132H • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lomustine • Nplate (romiplostim)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/13/2022","start_date":" 09/13/2022","primary_txt":" Primary completion: 12/19/2022","primary_completion_date":" 12/19/2022","study_txt":" Completion: 12/19/2022","study_completion_date":" 12/19/2022","last_update_posted":"2023-05-24"},{"id":"9ffbba93-5887-4ffe-9dc0-e10ed0790acb","acronym":"MGMTLiberati","url":"https://clinicaltrials.gov/study/NCT03542097","created_at":"2021-01-18T17:25:44.896Z","updated_at":"2024-07-02T16:35:47.966Z","phase":"","brief_title":"Assessment of MGMT Promoter Methylation in Advanced Ewing Sarcoma Treated With Temozolomide and Irinotecan","source_id_and_acronym":"NCT03542097 - MGMTLiberati","lead_sponsor":"Istituto Ortopedico Rizzoli","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • irinotecan"],"overall_status":"Completed","enrollment":" Enrollment 82","initiation":"Initiation: 04/15/2014","start_date":" 04/15/2014","primary_txt":" Primary completion: 12/31/2018","primary_completion_date":" 12/31/2018","study_txt":" Completion: 06/30/2019","study_completion_date":" 06/30/2019","last_update_posted":"2023-05-15"},{"id":"cbadce45-fb7f-4911-a4b0-3908019f7b36","acronym":"","url":"https://clinicaltrials.gov/study/NCT04091503","created_at":"2021-01-18T20:01:25.337Z","updated_at":"2024-07-02T16:35:49.759Z","phase":"Phase 1","brief_title":"Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma","source_id_and_acronym":"NCT04091503","lead_sponsor":"Center Trials \u0026 Treatment Europe","biomarkers":" IDH2 • MGMT","pipe":" | ","alterations":" IDH2 mutation • MGMT promoter methylation","tags":["IDH2 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • MGMT promoter methylation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 12/20/2019","start_date":" 12/20/2019","primary_txt":" Primary completion: 09/21/2022","primary_completion_date":" 09/21/2022","study_txt":" Completion: 10/28/2022","study_completion_date":" 10/28/2022","last_update_posted":"2023-04-25"},{"id":"aba61f37-944c-4f46-9ec5-54afdf036ced","acronym":"SIB-DOPA","url":"https://clinicaltrials.gov/study/NCT05653622","created_at":"2022-12-16T15:58:38.098Z","updated_at":"2024-07-02T16:35:54.068Z","phase":"Phase 2","brief_title":"Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma","source_id_and_acronym":"NCT05653622 - SIB-DOPA","lead_sponsor":"Institut de cancérologie Strasbourg Europe","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2023-03-06"},{"id":"9f076b35-59ec-4151-bae2-fc18060e5d0b","acronym":"CATARTIC","url":"https://clinicaltrials.gov/study/NCT05136326","created_at":"2021-11-29T14:53:37.958Z","updated_at":"2024-07-02T16:35:54.378Z","phase":"Phase 2","brief_title":"Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer","source_id_and_acronym":"NCT05136326 - CATARTIC","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation • MGMT expression","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation • MGMT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • capecitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-03-01"},{"id":"da6b2c7b-0baa-4b53-8f8f-39c5005bb54b","acronym":"ERASE-TMZ","url":"https://clinicaltrials.gov/study/NCT05031975","created_at":"2021-09-02T14:52:53.558Z","updated_at":"2024-07-02T16:36:04.553Z","phase":"Phase 2","brief_title":"Temozolomide and Irinotecan in Patients With MGMT Silenced Colorectal Cancer After Adjuvant Chemotherapy","source_id_and_acronym":"NCT05031975 - ERASE-TMZ","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" MGMT • CEACAM5","pipe":" | ","alterations":" MGMT promoter methylation • MGMT expression","tags":["MGMT • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation • MGMT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • irinotecan"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 05/02/2022","start_date":" 05/02/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2022-09-02"},{"id":"89d39d07-bc8c-450c-86ad-efad94592bd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04689347","created_at":"2021-01-19T20:48:19.485Z","updated_at":"2024-07-02T16:36:14.119Z","phase":"Phase 1b","brief_title":"5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.","source_id_and_acronym":"NCT04689347","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" BRAF • MGMT","pipe":" | ","alterations":" MGMT promoter methylation • MGMT expression","tags":["BRAF • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation • MGMT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • temozolomide • irinotecan • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/01/2021","start_date":" 01/01/2021","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 01/01/2023","study_completion_date":" 01/01/2023","last_update_posted":"2022-04-04"}]